Wolfgang Haas Selected Research

Bacterial Conjunctivitis

5/2012	Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.
12/2011	High proportion of nontypeable Streptococcus pneumoniae isolates among sporadic, nonoutbreak cases of bacterial conjunctivitis.
1/2011	Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes.
1/2011	Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile.
7/2010	Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.
9/2009	Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
5/2009	Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wolfgang Haas Research Topics

Disease

7	Bacterial Conjunctivitis 05/2012 - 05/2009
6	Infections 01/2016 - 01/2002
4	Eye Infections 12/2015 - 08/2009
2	Endophthalmitis (Ophthalmia) 01/2016 - 12/2015
1	Keratitis 12/2015
1	Mycoses (Diseases, Fungus) 12/2015
1	Conjunctivitis 11/2014
1	Autolysis 12/2004

Drug/Important Bio-Agent (IBA)

7	besifloxacin FDA Link 05/2012 - 05/2009
4	Anti-Bacterial Agents (Antibiotics)IBA 05/2012 - 01/2002
4	FluoroquinolonesIBA 05/2012 - 08/2009
4	SuspensionsIBA 01/2011 - 05/2009
2	Capsules (Microcapsules)IBA 11/2014 - 12/2011
2	Virulence Factors (Pathogenicity Factors)IBA 11/2014 - 12/2011
2	Erythromycin (Erycette)FDA LinkGeneric 12/2011 - 12/2004
2	Moxifloxacin (Avelox)FDA Link 01/2011 - 09/2009
2	Ophthalmic Solutions (Eye Drops)IBA 01/2011 - 09/2009
1	Hypochlorous Acid (Hypochlorite)IBA 12/2015
1	VaccinesIBA 11/2014
1	Tetracycline (Achromycin)FDA LinkGeneric 12/2011
1	Azithromycin (Zithromax)FDA LinkGeneric 12/2011
1	Trimethoprim (Proloprim)FDA LinkGeneric 12/2011
1	LactamsIBA 10/2011
1	AminoglycosidesIBA 10/2011
1	Cephalosporins (Cephalosporin Antibiotics)IBA 10/2011
1	Chloramphenicol (Chloromycetin)FDA Link 10/2011
1	GlycopeptidesIBA 10/2011
1	MacrolidesIBA 10/2011
1	Vancomycin FDA LinkGeneric 12/2004
1	ExotoxinsIBA 04/2004
1	PerforinIBA 04/2004

Therapy/Procedure

1	Antibiotic Prophylaxis 01/2016